We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SeaSpine (SPNE) Moves 5.8% Higher: Will This Strength Last?
Read MoreHide Full Article
SeaSpine Holdings shares rallied 5.8% in the last trading session to close at $10.92. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.4% loss over the past four weeks.
SeaSpine Holdings recorded a strong price increase on investors’ optimism surrounding the company’s upcoming first quarter 2022 results, which is set to release on May 3, after the closing bell. In the last-reported fourth quarter 2021, the company recorded loss of 52 cents per share, much wider than the Zacks Consensus Estimate of a loss of 36 cents per share. The company’s revenues of $55.6 million for the fourth quarter surpassed the Zacks Consensus Estimate by 1.3%. SeaSpine Holdings expects to report first quarter revenues in the band of $48.5-$49.5 million, reflecting growth of nearly 16%-18% year over year. The Zacks Consensus Estimates for the company’s earnings and revenues also suggest strong year over year growth.
This medical technology company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +23.9%. Revenues are expected to be $48.92 million, up 16.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For SeaSpine, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SPNE going forward to see if this recent jump can turn into more strength down the road.
SeaSpine belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Masimo (MASI - Free Report) , closed the last trading session 4.8% higher at $136.33. Over the past month, MASI has returned -17.8%.
Masimo's consensus EPS estimate for the upcoming report has changed +4.1% over the past month to $0.92. Compared to the company's year-ago EPS, this represents a change of +2.2%. Masimo currently boasts a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
SeaSpine (SPNE) Moves 5.8% Higher: Will This Strength Last?
SeaSpine Holdings shares rallied 5.8% in the last trading session to close at $10.92. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.4% loss over the past four weeks.
SeaSpine Holdings recorded a strong price increase on investors’ optimism surrounding the company’s upcoming first quarter 2022 results, which is set to release on May 3, after the closing bell. In the last-reported fourth quarter 2021, the company recorded loss of 52 cents per share, much wider than the Zacks Consensus Estimate of a loss of 36 cents per share. The company’s revenues of $55.6 million for the fourth quarter surpassed the Zacks Consensus Estimate by 1.3%. SeaSpine Holdings expects to report first quarter revenues in the band of $48.5-$49.5 million, reflecting growth of nearly 16%-18% year over year. The Zacks Consensus Estimates for the company’s earnings and revenues also suggest strong year over year growth.
This medical technology company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +23.9%. Revenues are expected to be $48.92 million, up 16.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For SeaSpine, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SPNE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
SeaSpine belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Masimo (MASI - Free Report) , closed the last trading session 4.8% higher at $136.33. Over the past month, MASI has returned -17.8%.
Masimo's consensus EPS estimate for the upcoming report has changed +4.1% over the past month to $0.92. Compared to the company's year-ago EPS, this represents a change of +2.2%. Masimo currently boasts a Zacks Rank of #4 (Sell).